Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.

Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.

Alcohol is an established carcinogen but not an established risk factor for prostate cancer, despite some recent prospective studies suggesting increased risk among heavy drinkers. The aim of this study was to investigate the role of alcohol on prostate-specific antigen (PSA) levels and prostate can...

Full description

Bibliographic Details
Main Authors:	Zuccolo, L, Lewis, S, Donovan, J, Hamdy, F, Neal, D, Smith, G
Format:	Journal article
Language:	English
Published:	2013

Similar Items

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
by: Burton, A, et al.
Published: (2013)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
by: Rosario, D, et al.
Published: (2008)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
by: Catto, J, et al.
Published: (2011)

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study
by: Catto, J, et al.
Published: (2011)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
by: Collin, S, et al.
Published: (2009)

Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
by: Dimitropoulou, P, et al.
Published: (2011)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.
by: Dimitropoulou, P, et al.
Published: (2011)

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
by: J. Donovan, et al.
Published: (2003-01-01)

PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis.
by: Murad, A, et al.
Published: (2009)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
by: Lane, J, et al.
Published: (2004)

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
by: Murad, A, et al.
Published: (2011)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: The ProtecT three-arm RCT
by: Hamdy, FC, et al.
Published: (2020)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT
by: Freddie C Hamdy, et al.
Published: (2020-08-01)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
by: Hamdy, F, et al.
Published: (2006)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
by: Lane, J, et al.
Published: (2010)

Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.
by: Mills, N, et al.
Published: (2003)

Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
by: Adams, Charleen D., et al.
Published: (2018)

The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?
by: Hamdy, F
Published: (2017)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
by: Rosario, D, et al.
Published: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
by: Rosario, D, et al.
Published: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
by: Rosario, D, et al.
Published: (2012)

Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
by: Johnston, T, et al.
Published: (2016)

A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study).
by: Murad, A, et al.
Published: (2010)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
by: Wade, J, et al.
Published: (2015)

The ProtecT trial: Analysis of the patient cohort, baseline risk stratification and disease progression
by: Young, GJ, et al.
Published: (2020)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
by: Donovan, J, et al.
Published: (2003)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.
by: Er, V, et al.
Published: (2017)

The value of repeat serum PSA measurements in the detection of prostate cancer - Experience from the feasibility phase of the UK protect study
by: Hamdy, F, et al.
Published: (2006)

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
by: Lane, A, et al.
Published: (2016)

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).
by: Mills, N, et al.
Published: (2006)

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
by: Donovan, JL, et al.
Published: (2017)

Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT
by: Isaac Yi Kim
Published: (2023-07-01)

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
by: S. Sanghera, et al.
Published: (2020-10-01)

Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study
by: Avery, K, et al.
Published: (2007)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
by: Burton, A, et al.
Published: (2011)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
by: Naseruddin Höti, et al.
Published: (2023-02-01)

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
by: Neal, D, et al.
Published: (2019)

Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
by: Avery, K, et al.
Published: (2008)

Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
by: Joanna C. Thorn, et al.
Published: (2023-06-01)

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.
by: Rebecca Gilbert, et al.
Published: (2015-01-01)